Trump to Big Pharma: Cut Drug Prices in 60 Days or Face Consequences

What Happened

President Trump has issued an ultimatum to 17 of the world’s largest pharmaceutical companies. They must lower their U.S. drug prices within 60 days or face consequences. The move targets drugmakers such as Pfizer, Johnson & Johnson, Eli Lilly, AstraZeneca, and Novartis. It demands that they offer Americans the same discounted prices they charge patients in Europe, Canada, and other wealthy nations.

The White House is pushing for “most-favored-nation” pricing. This would require pharmaceutical firms to match the lowest prices they charge abroad. Trump’s letter to CEOs calls the current pricing system an “unacceptable burden” on American families. Many medications cost two to three times more than in other developed countries.

If the companies don’t comply, the administration says it’s ready to use “every tool in our arsenal.” This likely references regulatory crackdowns, tariffs, or new pricing rules that could reshape the U.S. drug market.

Why It Matters

Americans have long paid the highest drug prices in the world. This is largely because pharmaceutical companies set U.S. prices independently of what they charge elsewhere. While other nations negotiate prices or cap costs, the U.S. has traditionally allowed firms to charge whatever the market can bear.

I've just identified the single crypto that's positioned to explode from J.P. Morgan and BlackRock's massive blockchain initiative.

This isn't speculation—the world's largest financial institutions are actively moving real-world assets onto the blockchain RIGHT NOW.

When trillions in assets migrate to this specific protocol, early investors could see gains of 10X, 50X, or potentially even 150X+:

Discover our #1 coin for Summer 2025 now (limited window of opportunity).

The window for early positioning is closing fast as institutional money floods in.

Trump’s plan aims to stop what he called “global freeloading.” Other countries benefit from U.S.-driven research and innovation but pay substantially less for the exact same medicines. The administration asserts that Americans are effectively subsidizing cheap drugs for the rest of the world.

Many believe that this is a long-overdue move to rebalance the system. It would force pharmaceutical companies to treat American patients more fairly. While certainly fewer in number than those in favor, there are critics (including many in the drug industry) who warn that price controls could stifle innovation. They also warn it could lead to reduced access to cutting-edge therapies.

The proposal builds on Trump’s May executive order. Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients called for global pricing parity on Medicaid-covered drugs and newly launched treatments.

How It Affects Readers

Supposing the policy goes through and drugmakers comply, millions of Americans could see lower out-of-pocket costs. This applies to everything from insulin to cholesterol medications. For seniors and low-income patients especially, these savings would be considerable, and even life changing.

But the outcome isn’t guaranteed. The pharmaceutical industry has one of the most powerful lobbying arms in the country and a history of fighting price reforms in court. There’s also concern that companies could respond by pulling certain drugs from the U.S. market or limiting new launches. That is something that has been seen in other countries with aggressive price controls.

But for now, the 60-day clock is ticking. Whether the industry bends to Trump’s demands or digs its heels in for an intense legal battle remains to be seen. For the time being, the Trump administration would appear to be framing this as a fight between American families and global pharma giants. They’re making a bet that public opinion stands on its side.